<DOC>
	<DOC>NCT00807794</DOC>
	<brief_summary>To evaluate the clinical safety of different doses of MEDI-507 through day 33.</brief_summary>
	<brief_title>A Safety Clinical Trial of Different Doses of MEDI-507 in the Prevention of Acute Renal Allograft Rejection</brief_title>
	<detailed_description>To evaluate the pharmacokinetic characteristics of MEDI-507 given in dose intervals.</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<criteria>Renal allograft recipients receiving their first or second allograft Age over 18 Maintained on conventional immunosuppression Completed informed consent document Known hypersensitivity to MEDI507 More than two renal allografts Moribund and unlikely (in the opinion of the investigator) to survive the duration of the trial Simultaneous use of other investigational agents (this does not include the use of licensed agents for indications not listed in the package insert) Any of the following clinical settings or diagnoses posttransplant: pregnancy or nursing mother: Ø Human Immunodeficiency Virus infection Ø hemodialysis or chronic peritoneal dialysis Ø use of a ventilator Ø hyperacute rejection Having received OKT3, tacrolimus, or antilymphocyte globulin during the current allograft Less than 10 ml/hr average urine output over 4 hours since the end of surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
</DOC>